APA

Chanan-Khan A., Cramer P., Demirkan F., Fraser G., Silva R. S., Grosicki S., Pristupa A., Janssens A., Mayer J., Bartlett N. L., Dilhuydy M., Pylypenko H., Loscertales J., Avigdor A., Rule S., Villa D., Samoilova O., Panagiotidis P., Goy A., Mato A., Pavlovsky M. A., Karlsson C., Mahler M., Salman M., Sun S., Phelps C., Balasubramanian S., Howes A. & Hallek M. (20160628). Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. : The Lancet. Oncology.

Chicago

Chanan-Khan Asher, Cramer Paula, Demirkan Fatih, Fraser Graeme, Silva Rodrigo Santucci, Grosicki Sebastian, Pristupa Aleksander, Janssens Ann, Mayer Jiri, Bartlett Nancy L, Dilhuydy Marie-Sarah, Pylypenko Halyna, Loscertales Javier, Avigdor Abraham, Rule Simon, Villa Diego, Samoilova Olga, Panagiotidis Panagiots, Goy Andre, Mato Anthony, Pavlovsky Miguel A, Karlsson Claes, Mahler Michelle, Salman Mariya, Sun Steven, Phelps Charles, Balasubramanian Sriram, Howes Angela and Hallek Michael. 20160628. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. : The Lancet. Oncology.

Harvard

Chanan-Khan A., Cramer P., Demirkan F., Fraser G., Silva R. S., Grosicki S., Pristupa A., Janssens A., Mayer J., Bartlett N. L., Dilhuydy M., Pylypenko H., Loscertales J., Avigdor A., Rule S., Villa D., Samoilova O., Panagiotidis P., Goy A., Mato A., Pavlovsky M. A., Karlsson C., Mahler M., Salman M., Sun S., Phelps C., Balasubramanian S., Howes A. and Hallek M. (20160628). Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. : The Lancet. Oncology.

MLA

Chanan-Khan Asher, Cramer Paula, Demirkan Fatih, Fraser Graeme, Silva Rodrigo Santucci, Grosicki Sebastian, Pristupa Aleksander, Janssens Ann, Mayer Jiri, Bartlett Nancy L, Dilhuydy Marie-Sarah, Pylypenko Halyna, Loscertales Javier, Avigdor Abraham, Rule Simon, Villa Diego, Samoilova Olga, Panagiotidis Panagiots, Goy Andre, Mato Anthony, Pavlovsky Miguel A, Karlsson Claes, Mahler Michelle, Salman Mariya, Sun Steven, Phelps Charles, Balasubramanian Sriram, Howes Angela and Hallek Michael. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. : The Lancet. Oncology. 20160628.